MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.78% | 48.05% | 46.28% | 35.83% | 35.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.17% | 156.21% | 179.87% | 164.38% | 94.55% |
| Operating Income | -111.17% | -156.21% | -179.87% | -164.38% | -94.55% |
| Income Before Tax | -158.70% | -208.07% | -222.80% | -175.01% | -56.75% |
| Income Tax Expenses | 41.64% | 71.51% | 138.16% | 199.15% | 367.70% |
| Earnings from Continuing Operations | -158.29% | -207.55% | -222.52% | -175.06% | -57.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 62.69% | -13.86% | -49.18% | -71.39% | -71.81% |
| Net Income | -160.62% | -221.44% | -256.99% | -230.31% | -76.82% |
| EBIT | -111.17% | -156.21% | -179.87% | -164.38% | -94.55% |
| EBITDA | -110.93% | -156.05% | -179.17% | -161.88% | -92.12% |
| EPS Basic | -157.74% | -208.47% | -206.97% | -147.85% | -19.67% |
| Normalized Basic EPS | -159.66% | -218.89% | -231.54% | -185.79% | -28.90% |
| EPS Diluted | -157.74% | -208.47% | -206.97% | -147.85% | -19.67% |
| Normalized Diluted EPS | -159.66% | -218.89% | -231.54% | -185.79% | -28.90% |
| Average Basic Shares Outstanding | 1.87% | 5.67% | 14.69% | 28.17% | 41.78% |
| Average Diluted Shares Outstanding | 1.87% | 5.67% | 14.69% | 28.17% | 41.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |